Nonspecific interstitial pneumonia and systemic sclerosis.
King
Talmadge E
TE
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D018893:Bronchoalveolar Lavage; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007962:Leukocytes / Q000378:metabolism; D017563:Lung Diseases, Interstitial / Q000209:etiology* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D011653:Pulmonary Diffusing Capacity / Q000502:physiology; D012129:Respiratory Function Tests; D012595:Scleroderma, Systemic / Q000150:complications* / Q000401:mortality / Q000473:pathology; D013256:Steroids; D014797:Vital Capacity / Q000502:physiology
D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D013256:Steroids